Status:
COMPLETED
Correlation Between Hepatic Fibrosis and Cardiovascular Risk Evaluated by Non-invasive Tests in Patients With NAFLD
Lead Sponsor:
Clinique Pasteur
Conditions:
NAFLD
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to examine the link between Non-Alcoholic Fatty Liver Disease (NAFLD) and cardiovascular diseases by studying the association between liver fibrosis degree and cardiovascular risk fact...
Detailed Description
Hepatic Fibrosis and Cardiovascular Risk are evaluated by non invasive tests
Eligibility Criteria
Inclusion
- NAFLD patients regardless of disease stage of severity (from simple steatosis to cirrhosis)
- Patient without known heart disease
- Patient agreeing to participate and who has given his non opposition
Exclusion
- Association with another cause of liver disease
- Already known coronary artery disease
- Pregnancy or breastfeeding in progress
Key Trial Info
Start Date :
March 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2025
Estimated Enrollment :
292 Patients enrolled
Trial Details
Trial ID
NCT04774302
Start Date
March 18 2021
End Date
April 30 2025
Last Update
June 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique Pasteur
Toulouse, France, 31 076